Medicament comprising recombinant antibody against chemokine receptor CCR4
US9675625B2 · kind B2 · utility
0Cited by
3References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 17, 2013 |
| Grant date | Jun 13, 2017 |
| Priority date | — |
| Expiry date | Nov 28, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K16/2866
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A medicament having a higher therapeutic effect than that provided by administration of a recombinant antibody against human CC chemokine receptor 4 or an antibody fragment thereof or an agent alone is provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.